Revolution Medicines (RVMD) Stock Forecast & Price Target

Compare

393 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RVMD Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Revolution

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RVMD Stock 12 Month Forecast

Average Price Target

$70.88

▲(90.59%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $70.88 with a high forecast of $80.00 and a low forecast of $57.00. The average price target represents a 90.59% change from the last price of $37.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","81":"$81","44.25":"$44.3","56.5":"$56.5","68.75":"$68.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$57.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,44.25,56.5,68.75,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.89,40.206153846153846,43.52230769230769,46.83846153846154,50.15461538461538,53.470769230769235,56.786923076923074,60.10307692307693,63.419230769230765,66.73538461538462,70.05153846153846,73.36769230769231,76.68384615384616,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.89,39.504615384615384,42.11923076923077,44.73384615384615,47.348461538461535,49.96307692307692,52.5776923076923,55.19230769230769,57.80692307692307,60.42153846153846,63.03615384615384,65.65076923076923,68.26538461538462,{"y":70.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.89,38.43692307692308,39.98384615384615,41.53076923076923,43.07769230769231,44.62461538461538,46.17153846153846,47.71846153846154,49.26538461538462,50.81230769230769,52.35923076923077,53.90615384615384,55.45307692307692,{"y":57,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.81,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$70.88

Lowest Price Target$57.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert BurnsH.C. Wainwright

H.C. Wainwright

$72

Buy

93.60%

Upside

Reiterated

07/01/25

Strategic Collaboration and Promising Trial Results Drive Buy Rating for Revolution Medicines

Jonathan ChangLeerink Partners

Leerink Partners

$66

Buy

77.47%

Upside

Reiterated

06/30/25

Promising Prospects for Revolution Medicines' Daraxonrasib in Pancreatic Cancer Treatment

Peter LawsonBarclays

Barclays

$72

Buy

93.60%

Upside

Reiterated

06/25/25

Barclays Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Michael SchmidtGuggenheim

Guggenheim

$80

Buy

115.11%

Upside

Reiterated

06/24/25

Revolution Medicines (RVMD) Receives a Buy from Guggenheim

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/24/25

We continue to view RVMD as a large-cap in the making and reiterate our Buy rating.

Ami FadiaNeedham

Needham

$57

Buy

53.27%

Upside

Reiterated

06/24/25

Strategic Partnership with Royalty Pharma Enhances Revolution Medicines' Financial Flexibility and Growth Potential

Alec StranahanBank of America Securities

Bank of America Securities

$78

Buy

109.73%

Upside

Reiterated

06/24/25

Revolution Medicines: Strategic Partnership and Promising Trials Drive Buy Rating

Jay OlsonOppenheimer

Oppenheimer

$75

Buy

101.67%

Upside

Reiterated

06/03/25

Revolution Medicines (RVMD) Gets a Buy from Oppenheimer

Robert DriscollWedbush

Wedbush

$67

Buy

80.16%

Upside

Reiterated

05/08/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Generation Bio (GBIO)

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$78→$64

Buy

72.09%

Upside

Reiterated

04/01/25

Revolution (RVMD) PT Lowered to $64 at StifelStifel analyst Ben Burnett lowered the price target on Revolution (NASDAQ: RVMD) to $64.00 (from $78.00) while maintaining a Buy rating.

Joseph CatanzaroPiper Sandler

Piper Sandler

$70

Buy

88.22%

Upside

Reiterated

02/27/25

Piper Sandler Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Eric JosephJ.P. Morgan

J.P. Morgan

$71→$70

Buy

88.22%

Upside

Reiterated

02/27/25

J.P. Morgan Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Eliana MerleUBS

UBS

$65→$71

Buy

90.91%

Upside

Reiterated

01/08/25

Revolution Medicines price target raised to $71 from $65 at UBSRevolution Medicines price target raised to $71 from $65 at UBS

Kelly ShiJefferies

Jefferies

$86

Buy

131.24%

Upside

Reiterated

12/20/24

Jefferies Keeps Their Buy Rating on Revolution Medicines (RVMD)

Laura PrendergastRaymond James

Raymond James

$48

Buy

29.07%

Upside

Reiterated

09/12/24

Revolution Medicines added to Analyst Current Favorites list at Raymond JamesRevolution Medicines added to Analyst Current Favorites list at Raymond James

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert BurnsH.C. Wainwright

H.C. Wainwright

$72

Buy

93.60%

Upside

Reiterated

07/01/25

Strategic Collaboration and Promising Trial Results Drive Buy Rating for Revolution Medicines

Jonathan ChangLeerink Partners

Leerink Partners

$66

Buy

77.47%

Upside

Reiterated

06/30/25

Promising Prospects for Revolution Medicines' Daraxonrasib in Pancreatic Cancer Treatment

Peter LawsonBarclays

Barclays

$72

Buy

93.60%

Upside

Reiterated

06/25/25

Barclays Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Michael SchmidtGuggenheim

Guggenheim

$80

Buy

115.11%

Upside

Reiterated

06/24/25

Revolution Medicines (RVMD) Receives a Buy from Guggenheim

Marc FrahmTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/24/25

We continue to view RVMD as a large-cap in the making and reiterate our Buy rating.

Ami FadiaNeedham

Needham

$57

Buy

53.27%

Upside

Reiterated

06/24/25

Strategic Partnership with Royalty Pharma Enhances Revolution Medicines' Financial Flexibility and Growth Potential

Alec StranahanBank of America Securities

Bank of America Securities

$78

Buy

109.73%

Upside

Reiterated

06/24/25

Revolution Medicines: Strategic Partnership and Promising Trials Drive Buy Rating

Jay OlsonOppenheimer

Oppenheimer

$75

Buy

101.67%

Upside

Reiterated

06/03/25

Revolution Medicines (RVMD) Gets a Buy from Oppenheimer

Robert DriscollWedbush

Wedbush

$67

Buy

80.16%

Upside

Reiterated

05/08/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Generation Bio (GBIO)

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$78→$64

Buy

72.09%

Upside

Reiterated

04/01/25

Revolution (RVMD) PT Lowered to $64 at StifelStifel analyst Ben Burnett lowered the price target on Revolution (NASDAQ: RVMD) to $64.00 (from $78.00) while maintaining a Buy rating.

Joseph CatanzaroPiper Sandler

Piper Sandler

$70

Buy

88.22%

Upside

Reiterated

02/27/25

Piper Sandler Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Eric JosephJ.P. Morgan

J.P. Morgan

$71→$70

Buy

88.22%

Upside

Reiterated

02/27/25

J.P. Morgan Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Eliana MerleUBS

UBS

$65→$71

Buy

90.91%

Upside

Reiterated

01/08/25

Revolution Medicines price target raised to $71 from $65 at UBSRevolution Medicines price target raised to $71 from $65 at UBS

Kelly ShiJefferies

Jefferies

$86

Buy

131.24%

Upside

Reiterated

12/20/24

Jefferies Keeps Their Buy Rating on Revolution Medicines (RVMD)

Laura PrendergastRaymond James

Raymond James

$48

Buy

29.07%

Upside

Reiterated

09/12/24

Revolution Medicines added to Analyst Current Favorites list at Raymond JamesRevolution Medicines added to Analyst Current Favorites list at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

1 Month

xxx

Success Rate

9/18 ratings generated profit

Average Return

+2.80%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.80% per trade.

3 Months

xxx

Success Rate

10/17 ratings generated profit

Average Return

+8.12%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +8.12% per trade.

1 Year

Benjamin BurnettStifel Nicolaus

Success Rate

10/16 ratings generated profit

Average Return

+15.32%

reiterated a buy rating 3 months ago

Copying Benjamin Burnett's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +15.32% per trade.

2 Years

xxx

Success Rate

10/16 ratings generated profit

Average Return

+21.53%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +21.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVMD Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RVMD has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the past 3 months is 70.88.

Each month's total comprises the sum of three months' worth of ratings.

RVMD Financial Forecast

RVMD Earnings Forecast

Next quarter’s earnings estimate for RVMD is -$1.12 with a range of -$1.19 to -$1.01. The previous quarter’s EPS was -$1.13. RVMD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year RVMD has Preformed in-line its overall industry.

RVMD Sales Forecast

Next quarter’s sales forecast for RVMD is $30.59M with a range of $0.00 to $250.00M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year RVMD has Preformed in-line its overall industry.

RVMD Stock Forecast FAQ

What is RVMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Revolution Medicines’s 12-month average price target is 70.88.

What is RVMD’s upside potential, based on the analysts’ average price target?

Revolution Medicines has 90.59% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RVMD a Buy, Sell or Hold?

Revolution Medicines has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Revolution Medicines’s price target?

The average price target for Revolution Medicines is 70.88. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $57.00. The average price target represents 90.59% Increase from the current price of $37.19.

What do analysts say about Revolution Medicines?

Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of RVMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Revolution Medicines (RVMD) Stock Forecast & Price Target

RVMD Analyst Ratings

RVMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revolution Medicines

RVMD Analyst Recommendation Trends

RVMD Financial Forecast

RVMD Earnings Forecast

RVMD Sales Forecast

RVMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts